The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Roy W Jones; Miia Kivipelto; Howard Feldman; Larry Sparks; Rachelle Doody; David D Waters; Judith Hey-Hadavi; Andrei Breazna; Rachel J Schindler; Harry Ramos; LEADe Investigators; Peter Passmore

doi:10.1016/j.jalz.2008.02.001

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Roy W Jones
, Miia Kivipelto
, Howard Feldman
, Larry Sparks
, Rachelle Doody
, David D Waters
, Judith Hey-Hadavi
, Andrei Breazna
, Rachel J Schindler
, Harry Ramos
, LEADe Investigators
, Peter Passmore

Research output: Contribution to journal › Article › peer-review

62 Citations (Scopus)

Abstract

Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

Original language	English
Pages (from-to)	145-53
Number of pages	9
Journal	Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume	4
Issue number	2
DOIs	https://doi.org/10.1016/j.jalz.2008.02.001
Publication status	Published - Mar 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Epidemiology
Geriatrics and Gerontology
Health Policy
Clinical Neurology
Psychiatry and Mental health
Cellular and Molecular Neuroscience
Developmental Neuroscience

Access to Document

10.1016/j.jalz.2008.02.001

Cite this

Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L., Doody, R., Waters, D. D., Hey-Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., LEADe Investigators, & Passmore, P. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 4(2), 145-53. https://doi.org/10.1016/j.jalz.2008.02.001

@article{13e78021f724442bbf40a54555f76141,

title = "The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics",

abstract = "Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).",

author = "Jones, \{Roy W\} and Miia Kivipelto and Howard Feldman and Larry Sparks and Rachelle Doody and Waters, \{David D\} and Judith Hey-Hadavi and Andrei Breazna and Schindler, \{Rachel J\} and Harry Ramos and \{LEADe Investigators\} and Peter Passmore",

year = "2008",

month = mar,

doi = "10.1016/j.jalz.2008.02.001",

language = "English",

volume = "4",

pages = "145--53",

journal = "Alzheimer's \& Dementia: The Journal of the Alzheimer's Association",

publisher = "John Wiley \& Sons Inc.",

number = "2",

}

Jones, RW, Kivipelto, M, Feldman, H, Sparks, L, Doody, R, Waters, DD, Hey-Hadavi, J, Breazna, A, Schindler, RJ, Ramos, H, LEADe Investigators & Passmore, P 2008, 'The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics', Alzheimer's & Dementia: The Journal of the Alzheimer's Association, vol. 4, no. 2, pp. 145-53. https://doi.org/10.1016/j.jalz.2008.02.001

TY - JOUR

T1 - The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe)

T2 - design and baseline characteristics

AU - Jones, Roy W

AU - Kivipelto, Miia

AU - Feldman, Howard

AU - Sparks, Larry

AU - Doody, Rachelle

AU - Waters, David D

AU - Hey-Hadavi, Judith

AU - Breazna, Andrei

AU - Schindler, Rachel J

AU - Ramos, Harry

AU - LEADe Investigators

AU - Passmore, Peter

PY - 2008/3

Y1 - 2008/3

N2 - Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

AB - Growing evidence suggests that elevated cholesterol levels in mid-life are associated with increased risk of developing Alzheimer's disease (AD), and that statins might have a protective effect against AD and dementia. The Lipitor's Effect in Alzheimer's Dementia (LEADe) study tests the hypothesis that a statin (atorvastatin 80 mg daily) will provide a benefit on the course of mild to moderate AD in patients receiving background therapy of a cholinesterase inhibitor (donepezil 10 mg daily).

U2 - 10.1016/j.jalz.2008.02.001

DO - 10.1016/j.jalz.2008.02.001

M3 - Article

C2 - 18631958

VL - 4

SP - 145

EP - 153

JO - Alzheimer's & Dementia: The Journal of the Alzheimer's Association

JF - Alzheimer's & Dementia: The Journal of the Alzheimer's Association

IS - 2

ER -

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this